Oruka's Psoriasis Breakthrough and $180M Investment

ORKA-001, Oruka's new psoriasis drug, shows a 100-day half-life, making once-a-year dosing possible. It aims for higher skin clearance and long-term remission with a good safety profile. Phase 2 data is expected in late 2026. This could redefine treatment!